Peeters M, Réthoré M O, de Kermadec S, Lejeune J
Centre de Recherches Génétique Humaine et Maladies de l'Intelligence,Institut de Progenèse, Paris.
Ann Genet. 1989;32(4):211-3.
3,3'5'-triiodothyronine (rT3) levels have been documented to be low in patients with Down syndrome but the metabolic implications of this finding remain unknown. A highly significant correlation was found between the in vitro variations of the mitotic index in lymphocyte cultures when rT3 or known inhibitors of inosine monophosphate dehydrogenase: mycophenolic acid, 6-mercaptopurine or 2-3-diphosphoglycerate were added. No significant difference was found between the response of trisomy 21 or normal lymphocytes. The finding suggests that rT3 may be a physiological modulator of inosine monophosphate dehydrogenase. The implications on cellular differentiation are discussed.